| Autor: |
Machado CM; Virology Laboratory (LIM 52-HCFMUSP)--Institute of Tropical Medicine, University of São Paulo Medical School, São Paulo, Brazil. clarimm@usp.br, de Souza VA, Sumita LM, da Rocha IF, Dulley FL, Pannuti CS |
| Jazyk: |
angličtina |
| Zdroj: |
Bone marrow transplantation [Bone Marrow Transplant] 2005 Apr; Vol. 35 (8), pp. 787-91. |
| DOI: |
10.1038/sj.bmt.1704878 |
| Abstrakt: |
Measles vaccination has been recommended after the second year following bone marrow transplant (BMT) in patients not receiving immunosuppressive drugs. During a measles outbreak, we vaccinated all patients after the first year of transplant, and conducted a prospective trial to evaluate safety, effectiveness and sustained immunity after early vaccination. Patients received attenuated virus vaccine between 9 and 18 months after BMT. A total of 51 patients were evaluated and 27 of them (52.9%) were receiving immunosuppressive drugs. Only mild adverse reactions were noted. Nine patients (17.6%) were susceptible (IgG< or =100 mIU/ml) at vaccination, and all seroconverted. In those immune at vaccination, a four-fold increase in measles IgG titers was found in one of 34 patients (2.9%) with specific IgG> or =200 mIU/ml compared to 14 of 17 (82.3%) with IgG<200 mIU/ml (P< 0.0001). Sustained immunity after 24 months was more likely to occur in patients with specific IgG levels< or =200 or > or =500 mIU/mL (83.4 and 100%, respectively) in comparison to patients with 200
|
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
